Merck to Acquire EyeBio for Up to $3B, Re-Entering Eye Drug Space
Merck & Co. has agreed to acquire EyeBiotech (EyeBio) for up to $3 billion, the companies said today, in a deal that will return the buyer to the eye drug development segment it vacated about a decade ago. Based in London, EyeBio has developed a …